Exelixis, Inc. and Bausch Health Companies Inc.: A Detailed Gross Profit Analysis

Pharma Giants' Profit Trends: A Decade in Review

__timestampBausch Health Companies Inc.Exelixis, Inc.
Wednesday, January 1, 2014600890000023068000
Thursday, January 1, 2015785380000033277000
Friday, January 1, 20167063000000184902000
Sunday, January 1, 20176176000000437411000
Monday, January 1, 20186029000000827478000
Tuesday, January 1, 20196251000000934678000
Wednesday, January 1, 20205778000000951266000
Friday, January 1, 202160400000001382097000
Saturday, January 1, 202257600000001553153000
Sunday, January 1, 202361980000001757661000
Monday, January 1, 20242168701000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Companies: Gross Profit Trends from 2014 to 2023

In the ever-evolving landscape of the pharmaceutical industry, Exelixis, Inc. and Bausch Health Companies Inc. have showcased intriguing financial trajectories over the past decade. From 2014 to 2023, Bausch Health consistently maintained a robust gross profit, peaking in 2015 with a 30% increase from the previous year. However, a slight decline was observed in 2022, with profits dipping by approximately 4% compared to 2021.

Conversely, Exelixis, Inc. has demonstrated a remarkable growth story. Starting from a modest base in 2014, the company experienced a staggering 7,500% increase in gross profit by 2023. This growth trajectory highlights Exelixis's strategic advancements and market positioning.

These trends underscore the dynamic nature of the pharmaceutical sector, where strategic decisions and market conditions can significantly impact financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025